In the last trading session, 1.87 million Wave Life Sciences Ltd (NASDAQ:WVE) shares changed hands as the company’s beta touched -0.61. With the company’s per share price at $5.60 changed hands at -$0.2 or -3.45% during last session, the market valuation stood at $859.52M. WVE’s last price was a discount, traded about -198.93% off its 52-week high of $16.74. The share price had its 52-week low at $4.25, which suggests the last value was 24.11% up since then. When we look at Wave Life Sciences Ltd’s average trading volume, we note the 10-day average is 2.14 million shares, with the 3-month average coming to 1.14 million.
Analysts gave the Wave Life Sciences Ltd (WVE) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.17. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended WVE as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Wave Life Sciences Ltd’s EPS for the current quarter is expected to be -0.25.
Wave Life Sciences Ltd (NASDAQ:WVE) trade information
Instantly WVE was in red as seen at the end of in last trading. With action -27.65%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -54.73%, with the 5-day performance at -27.65% in the red. However, in the 30-day time frame, Wave Life Sciences Ltd (NASDAQ:WVE) is -40.36% down. Looking at the short shares, we see there were 8.34 million shares sold at short interest cover period of 7.26 days.
The consensus price target for the stock as assigned by Wall Street analysts is 22, meaning bulls need an upside of 74.55% from its current market value. According to analyst projections, WVE’s forecast low is 15 with 36 as the target high. To hit the forecast high, the stock’s price needs a -542.86% plunge from its current level, while the stock would need to soar -167.86% for it to hit the projected low.
Wave Life Sciences Ltd (WVE) estimates and forecasts
Year-over-year growth is forecast to reach -33.78% down from the last financial year.
Consensus estimates given by 10 financial analysts project the company’s revenue in the current quarter to hit an average of 11.65M. 9 analysts are of the opinion that Wave Life Sciences Ltd’s revenue for the current quarter will be 15.17M. The company’s revenue for the corresponding quarters a year ago was 12.54M and 19.69M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -7.09%. The estimates for the next quarter sales put growth at -22.99%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 34.27%. The 2025 estimates are for Wave Life Sciences Ltd earnings to decrease by -37.40%, but the outlook for the next 5-year period is at 0.47% per year.
WVE Dividends
Wave Life Sciences Ltd is expected to release its next quarterly earnings report on 2025-Mar-03.
Wave Life Sciences Ltd (NASDAQ:WVE)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 16.53% of Wave Life Sciences Ltd shares while 83.49% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 100.02%. There are 83.49% institutions holding the Wave Life Sciences Ltd stock share, with RA CAPITAL MANAGEMENT, L.P. the top institutional holder. As of 2024-06-30, the company held 14.0527% of the shares, roughly 18.2 million WVE shares worth $90.83 million.
MAVERICK CAPITAL LTD holds the second largest percentage of outstanding shares, with 5.9211% or 7.67 million shares worth $38.27 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jan 31, 2025 were PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund and iShares Trust-iShares Russell 2000 ETF . With 2.44 shares estimated at $13.68 million under it, the former controlled 1.59% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 1.55% of the shares, roughly 2.38 shares worth around $13.31 million.
